Metabolic pathway alterations in microvascular endothelial cells in response to hypoxia.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 06 04 2020
accepted: 07 05 2020
entrez: 10 7 2020
pubmed: 10 7 2020
medline: 12 9 2020
Statut: epublish

Résumé

The vasculature within a tumor is highly disordered both structurally and functionally. Endothelial cells that comprise the vasculature are poorly connected causing vessel leakage and exposing the endothelium to a hypoxic microenvironment. Therefore, most anti-angiogenic therapies are generally inefficient and result in acquired resistance to increased hypoxia due to elimination of the vasculature. Recent studies have explored the efficacy of targeting metabolic pathways in tumor cells in combination with anti-angiogenic therapy. However, the metabolic alterations of endothelial cells in response to hypoxia have been relatively unexplored. Here, we measured polar metabolite levels in microvascular endothelial cells exposed to short- and long-term hypoxia with the goal of identifying metabolic vulnerabilities that can be targeted to normalize tumor vasculature and improve drug delivery. We found that many amino acid-related metabolites were altered by hypoxia exposure, especially within alanine-aspartate-glutamate, serine-threonine, and cysteine-methionine metabolism. Additionally, there were significant changes in de novo pyrimidine synthesis as well as glutathione and taurine metabolism. These results provide key insights into the metabolic alterations that occur in endothelial cells in response to hypoxia, which serve as a foundation for future studies to develop therapies that lead to vessel normalization and more efficient drug delivery.

Identifiants

pubmed: 32645038
doi: 10.1371/journal.pone.0232072
pii: PONE-D-20-09862
pmc: PMC7347218
doi:

Substances chimiques

Amino Acids 0
Nucleotides 0
Aspartic Acid 30KYC7MIAI
Cysteine K848JZ4886

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0232072

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL007893
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA213460
Pays : United States

Déclaration de conflit d'intérêts

A.T. is a paid consultant of and received support via salary from Oncologie, Inc. and Bertis, Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Nat Med. 2001 Sep;7(9):987-9
pubmed: 11533692
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
Physiol Rev. 2018 Jan 1;98(1):3-58
pubmed: 29167330
Lancet. 2016 Jul 30;388(10043):518-29
pubmed: 26853587
Cancer Cell. 2016 Dec 12;30(6):968-985
pubmed: 27866851
Nat Rev Clin Oncol. 2012 Feb 14;9(5):297-303
pubmed: 22330688
Nat Metab. 2019 Jan;1(1):158-171
pubmed: 31106291
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11715-20
pubmed: 9751731
Cancer Cell. 2009 Mar 3;15(3):232-9
pubmed: 19249681
Microvasc Res. 1986 May;31(3):288-305
pubmed: 2423854
Cell Metab. 2018 Nov 6;28(5):706-720.e6
pubmed: 30122555
Curr Opin Genet Dev. 2011 Feb;21(1):73-9
pubmed: 21106363
EMBO J. 2017 Aug 1;36(15):2187-2203
pubmed: 28637793
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
Nat Rev Drug Discov. 2011 Jun;10(6):417-27
pubmed: 21629292
Cell. 2013 Aug 1;154(3):651-63
pubmed: 23911327
Cell Rep. 2019 Feb 26;26(9):2257-2265.e4
pubmed: 30811976
Annu Rev Physiol. 2019 Feb 10;81:483-503
pubmed: 30742787
Cancer Cell. 2004 Dec;6(6):553-63
pubmed: 15607960
Cancers (Basel). 2019 Dec 30;12(1):
pubmed: 31905922
Cancer Cell. 2015 Jan 12;27(1):123-37
pubmed: 25584895
Physiol Rev. 2011 Jul;91(3):1071-121
pubmed: 21742796
Cell. 2017 Feb 9;168(4):657-669
pubmed: 28187287
Cell Chem Biol. 2017 Sep 21;24(9):1161-1180
pubmed: 28938091
Nat Protoc. 2012 Apr 12;7(5):872-81
pubmed: 22498707
J Appl Physiol (1985). 2004 Oct;97(4):1358-66
pubmed: 15180977
Cell. 2015 Jul 30;162(3):540-51
pubmed: 26232224
Nat Cell Biol. 2018 Jul;20(7):775-781
pubmed: 29941933
Circ Res. 2005 Sep 30;97(7):637-44
pubmed: 16123331
Science. 2005 Jan 7;307(5706):58-62
pubmed: 15637262
Cancer Cell. 2014 Nov 10;26(5):605-22
pubmed: 25517747
Nat Rev Clin Oncol. 2011 May 31;8(7):393-404
pubmed: 21629216
Sci Signal. 2017 Dec 19;10(510):
pubmed: 29259101
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Trends Pharmacol Sci. 2006 Aug;27(8):438-46
pubmed: 16820223
Cancer Cell. 2009 Mar 3;15(3):220-31
pubmed: 19249680
Nucleic Acids Res. 2012 Aug;40(15):e115
pubmed: 22730293
Cancer Metab. 2014 Sep 15;2:19
pubmed: 25250177
Pflugers Arch. 2017 Jun;469(5-6):815-827
pubmed: 28176017
Nat Protoc. 2019 Feb;14(2):313-330
pubmed: 30683937
FASEB J. 2019 Jul;33(7):7929-7941
pubmed: 30917010
Annu Rev Physiol. 2019 Feb 10;81:505-534
pubmed: 30742782
PLoS One. 2015 Jan 29;10(1):e0116740
pubmed: 25633823
Cell Metab. 2019 Sep 3;30(3):414-433
pubmed: 31484054
Cancer Cell. 2003 Apr;3(4):347-61
pubmed: 12726861
Biochim Biophys Acta. 2013 May;1830(5):3143-53
pubmed: 22995213
Mol Cell Biol. 2003 Dec;23(24):9361-74
pubmed: 14645546
Cancer Cell. 2005 Oct;8(4):299-309
pubmed: 16226705
Clin Cancer Res. 2008 Oct 15;14(20):6371-5
pubmed: 18927275
Amino Acids. 2014 Jan;46(1):7-20
pubmed: 22810731
Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494
pubmed: 29762782
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
Physiol Genomics. 2004 Jun 17;18(1):70-8
pubmed: 15100389
Nat Cell Biol. 2018 Jul;20(7):782-788
pubmed: 29941931
Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):566-73
pubmed: 11950692
Circ Res. 2015 Mar 27;116(7):1231-44
pubmed: 25814684
Nat Rev Drug Discov. 2007 Apr;6(4):273-86
pubmed: 17396134
Antioxid Redox Signal. 2013 Feb 10;18(5):522-55
pubmed: 22667998
Trends Pharmacol Sci. 2009 Dec;30(12):624-30
pubmed: 19836845
Nature. 2002 Mar 21;416(6878):279-80
pubmed: 11907566
Angiogenesis. 2017 Feb;20(1):39-54
pubmed: 27699500
Cell. 2015 Jul 30;162(3):552-63
pubmed: 26232225
Pharmacogenomics J. 2003;3(3):183-8
pubmed: 12815367
Nat Protoc. 2006;1(3):1112-6
pubmed: 17406391
Trends Cancer. 2016 Dec;2(12):758-770
pubmed: 28741521
J Invest Dermatol. 1992 Dec;99(6):683-90
pubmed: 1361507

Auteurs

Emily B Cohen (EB)

Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.

Renee C Geck (RC)

Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.

Alex Toker (A)

Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.
Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH